Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide.

Autor: Zedan AH; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark. ahmed.zedan@rsyd.dk.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark. ahmed.zedan@rsyd.dk., Nederby L; Department of Biochemistry and Immunology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Volmer LM; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Madsen CV; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Sørensen BE; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark., Hansen TF; Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.; Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Oct 10; Vol. 13 (1), pp. 17144. Date of Electronic Publication: 2023 Oct 10.
DOI: 10.1038/s41598-023-43937-7
Abstrakt: Metastatic castration resistant prostate cancer (mCRPC) is still the lethal stage for the whole spectrum of prostate cancer disease. Even though different treatment options have been introduced in the last decade with a significant survival improvement for this population, a lack of more reliable prognostic and predictive markers is still one of the main clinical challenges in management of mCRPC. The aim of this study was to investigate the correlation between Natural Killer cell activity (NKA) and both treatment effect and outcomes in patients with mCRPC treated with enzalutamide. A total of 87 patients with mCRPC treated with enzalutamide as the first line treatment were enrolled. NKA was estimated at baseline and prior to each treatment cycle. Endpoints included both treatment effect with biochemical response (BR), biochemical progression (BP) and radiological progression (RP), as well as outcome data with overall survival (OS), radiologic progression free survival (rPFS), and time to next treatment (TTT). At the time of BR, interferon-gamma (IFNγ) decreased significantly compared to levels detected at baseline (z-score = 2.33, p = 0.019). Regarding outcome data, the whole cohort was divided into four groups according to the change of IFNγ level during the first 3 cycles of enzalutamide treatment. In group 1 (n = 42) the IFNγ level remained within a normal range (≥ 250 pg/mL),while in group 2 (n = 7) it increased from an abnormal (< 250 pg/mL) to a normal level. In group 3 (n = 13) it dropped to an abnormal level, and it remained at an abnormal level during treatment in group 4 (n = 17). Patients in group 2 showed the worst prognosis with shorter both rPFS and TTT (HR 4.30, p = 0.037; and HR 6.82, p = 0.011, respectively). In this study inverse correlations between NKA and both treatment response and outcomes was observed in mCRPC patients receiving enzalutamide, suggesting an unfavourable role of NK cells in the late stage of PCa.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje